文献速递肝病消化道肿瘤与早癌

阿司匹林使用与伴或不伴肝硬化的慢性乙型肝炎患者肝细胞癌风险

Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
PubMed 文献 · Hepatology · 2022-03-17

基于韩国国民健康保险服务数据库2007至2017年329,635例慢性乙型肝炎成人,比较连续使用阿司匹林≥90天者与从未使用抗血小板治疗者。倾向评分匹配队列中位随访6.7年,阿司匹林组10年肝细胞癌累积发生率9.5% vs 未治疗组11.3%(aSHR 0.85;95%CI 0.78-0.92),但肝硬化患者中该关联不明显(aSHR 1.00;95%CI 0.85-1.18)。

要点

  • 阿司匹林使用与慢性乙型肝炎成人肝细胞癌风险降低相关(aSHR 0.85;95%CI 0.78-0.92)。
  • 肝硬化状态显著影响阿司匹林与肝细胞癌风险的关联(交互作用P=0.04)。
  • 阿司匹林使用与肝脏相关死亡风险降低相关(aSHR 0.80;95%CI 0.71-0.90),未增加大出血风险(aSHR 1.09;95%CI 0.99-1.21)。

核心结论

  • 在慢性乙型肝炎成人中,阿司匹林使用与肝细胞癌风险和肝脏相关死亡风险降低相关;肝硬化状态对该关联有实质性影响。

研究设计与样本

  • 利用韩国国民健康保险服务数据库2007至2017年识别329,635例符合条件的慢性乙型肝炎成人,包括连续使用阿司匹林≥90天者20,200例和从未接受抗血小板治疗者309,435例。
  • 采用倾向评分匹配队列(19,003对),并考虑竞争风险,评估肝细胞癌、肝脏相关死亡和大出血风险。

主要发现

  • 中位随访6.7年,阿司匹林治疗组10年肝细胞癌累积发生率为9.5%,未治疗组为11.3%(aSHR 0.85;95%CI 0.78-0.92)。
  • 肝硬化患者(2,479对)中,阿司匹林使用与肝细胞癌风险的关联不明显(aSHR 1.00;95%CI 0.85-1.18)。
  • 肝硬化状态对阿司匹林使用与肝细胞癌风险的关联有显著影响(交互作用P=0.04)。
  • 阿司匹林使用与较低的肝脏相关死亡风险相关(aSHR 0.80;95%CI 0.71-0.90)。
  • 阿司匹林使用与大出血风险无显著关联(aSHR 1.09;95%CI 0.99-1.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Studies on differential effect of aspirin therapy on HCC risk across the spectrum of liver diseases are lacking. We investigated the association between aspirin use and risks of HCC, liver-associated death, and major bleeding in chronic hepatitis B (CHB) patients with or without cirrhosis. APPROACH AND RESULTS: We identified 329,635 eligible adults with CHB from 2007 through 2017, using the Korean National Health Insurance Service database, including patients who received aspirin for ≥90 consecutive days (n = 20,200) and patients who never received antiplatelet therapy (n = 309,435). Risks of HCC, liver-associated mortality, and major bleeding were estimated in a propensity-score-matched cohort (19,003 pairs), accounting for competing risks. With a median follow-up of 6.7 years, 10-year cumulative incidence of HCC was 9.5% in the aspirin-treated group and 11.3% in the untreated group (adjusted subdistribution hazard ratio [aSHR], 0.85; 95% CI, 0.78-0.92). However, among patients with cirrhosis (2479 pairs), an association of aspirin use with HCC risk was not evident (aSHR, 1.00; 95% CI, 0.85-1.18). Cirrhosis status had a significant effect on the association between aspirin use and HCC risk (pinteraction , n = 0.04). Aspirin use was also associated with lower liver-associated mortality (aSHR, 0.80; 95% CI, 0.71-0.90). Moreover, aspirin use was not associated with major bleeding risk (aSHR, 1.09; 95% CI, 0.99-1.21). CONCLUSIONS: Aspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB. Cirrhosis status had a substantial effect on the association between aspirin use and HCC risk.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Jang H, Lee YB, Moon H, et al. Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. Hepatology. 2022. PMID: 35100447. doi:10.1002/hep.32380

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。